WASHINGTON, D.C. – Escalating trade tensions between the United States and India are threatening to overshadow a previously strong bilateral relationship,as former President Donald Trump prepares to implement a 50% tariff on Indian goods. The move, slated for the coming weeks, is largely attributed to India’s continued purchase of Russian oil, despite U.S. sanctions.
The tariff increase, first reported by Foreign Policy, represents a important rupture in a partnership that has flourished for over two decades under multiple administrations. A senior Indian official, speaking to reporters in Washington D.C.on Thursday, August 8th, emphasized New Delhi’s desire to compartmentalize the trade dispute from other areas of cooperation, including defense and technology. “Our effort is to clearly realize that trade is trade and other discussions are other discussions. We have no intention to pause other aspects of the relationship,” the official stated. The official did not specify which defense or technology collaborations would continue unaffected.
This advancement occurs as the August 12th deadline approaches for a 90-day pause on higher tariffs on Chinese goods,initially agreed upon following bilateral trade talks in stockholm,Sweden,on July 26th. While both sides indicated a willingness to discuss an extension, no official confirmation has been issued as of today, August 9th. The Stockholm meeting involved U.S. Trade Representative Katherine Tai and Chinese Commerce Minister Wang Wentao.
Meanwhile, a potential meeting between Trump and Russian President Vladimir putin is anticipated sometime next week, adding another layer of geopolitical complexity to the situation. No specific location for the meeting has been announced.
The escalating tensions are further elaborate by domestic policy shifts within the U.S. Health and Human Services Department. Current Health Secretary Robert F. Kennedy Jr.’s recent decision to halt $500 million in U.S. government investments in mRNA vaccine research has drawn criticism from former Trump administration officials. Chris Meekins, a health official during the first Trump administration, labeled the move a “national security vulnerability” in a post on X (formerly Twitter) on August 8th, arguing that the funding served as a deterrent against the use of biological agents. Kennedy’s decision impacts funding allocated to projects at institutions like the National Institutes of Health (NIH) and various pharmaceutical companies.
Image: Family and friends of Palestinian activist awdah Hathaleen carry his body to the cemetery during his funeral in Umm al-Kheir, West Bank, on Aug. 7. (Tamir Kalifa/Getty Images)
